Work Here?
Overview
MedPharm is a contract development and manufacturing organization specializing in topical, transdermal, and mucosal drug delivery. It provides end-to-end services from formulation development through clinical and commercial manufacturing, including analytical testing and regulatory support, and operates proprietary delivery platforms such as MedSpray, MedTherm, and AquaRMed. Its capabilities cover dermal, pulmonary, nasal, ophthalmic, and other mucosal routes, combining research services with a patent portfolio to support product lifecycle needs. In 2024 it merged with Tergus Pharma to expand into hormone-based and highly potent drugs, with the goal of helping pharmaceutical and biotech customers move from early formulation to scalable, reliable manufacturing for clinical and commercial use.
About MedPharm
Industries
Industrial & Manufacturing
Biotechnology
Healthcare
Company Size
N/A
Company Stage
Grant
Total Funding
$390K
Headquarters
Guildford, United Kingdom
Founded
1999
Simplify's Take
What believers are saying
- The January 2026 FDA outcome strengthens sales into regulated commercial manufacturing accounts.
- Durham's 110,000-square-foot facility gives MedPharm room to win larger commercial contracts.
- Purna partnership broadens geographic reach and service breadth for 2026 cross-selling.
What critics are saying
- Ampersand's control after the Purna acquisition concentrates ownership and decision-making, risking strategic drift by 2026.
- Topical CDMO demand depends on few sponsor programs; one lost client can hit utilization within quarters.
- A failed Durham quality event would undermine MedPharm's core differentiation and commercial manufacturing credibility.
What makes MedPharm unique
- MedPharm's Durham site cleared FDA inspection on January 7, 2026, with no Form 483.
- The 2024 Tergus merger adds commercial manufacturing, serialization, hormones, and highly potent drug capabilities.
- MedPharm and Purna now combine transatlantic topical expertise with liquid and semi-solid manufacturing.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$390k
Above
Industry Average
Funded Over
1 Rounds
Company News
MedPharm, a Guildford, UK-based topical and transdermal Contract Development and Manufacturing Organization (CDMO) and Ampersand Capital Partners portfolio company, announced a merger with Tergus Pharma, a Research Triangle Park, NC-based end-to-end contract service provider and a Great Point Partners portfolio company
MedPharm, a UK-based CDMO, has merged with Tergus Pharma, a US-based contract service provider. The combined entity will operate under the MedPharm name, offering end-to-end drug development and manufacturing services. Michael Kane, Tergus Pharma CEO, will become CEO of MedPharm, while Patrick Walsh remains Executive Chairman. Great Point Partners retains a significant minority stake, with Ampersand Capital Partners and Bourne Partners Strategic Capital holding majority ownership.
MedPharm is Hiring for 18 Jobs on Simplify!
Find jobs on Simplify and start your career today
About MedPharm
Industries
Industrial & Manufacturing
Biotechnology
Healthcare
Company Size
N/A
Company Stage
Grant
Total Funding
$390K
Headquarters
Guildford, United Kingdom
Founded
1999
MedPharm is Hiring for 18 Jobs on Simplify!
Find jobs on Simplify and start your career today